Deletion of 5-lipoxygenase in the tumor microenvironment promotes lung cancer progression and metastasis through regulating t cell recruitment

Journal of Immunology

Volumn 196, Issue 2, 2016, Pages 891-901

  Poczobutt, Joanna M ^a   Nguyen, Teresa T ^a   Hanson, Dwight ^a   Li, Howard ^a,b   Sippel, Trisha R ^a   Weiser Evans, Mary C M ^a   Gijon, Miguel ^a   Murphy, Robert C ^a   Nemenoff, Raphael A ^a  

^a UNIVERSITY OF COLORADO   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARACHIDONATE 5 LIPOXYGENASE; CXCL9 CHEMOKINE; HYDROLASE; LEUKOTRIENE; MACROPHAGE INFLAMMATORY PROTEIN 3ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW; CANCER GROWTH; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DENDRITIC CELL; ENZYME ACTIVITY; FEMALE; LEWIS LUNG CARCINOMA CELL; LIVER METASTASIS; LUNG CANCER; MALE; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; T LYMPHOCYTE; TUMOR MICROENVIRONMENT; TUMOR VOLUME; ANIMAL; C57BL MOUSE; CANCER TRANSPLANTATION; DEFICIENCY; DISEASE COURSE; DISEASE MODEL; ENZYMOLOGY; FLOW CYTOMETRY; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; KNOCKOUT MOUSE; LEWIS CARCINOMA; LUNG TUMOR; PATHOLOGY; REAL TIME POLYMERASE CHAIN REACTION; TUMOR INVASION;

ANIMALS; ARACHIDONATE 5-LIPOXYGENASE; CARCINOMA, LEWIS LUNG; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; FLOW CYTOMETRY; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NEOPLASM INVASIVENESS; NEOPLASM TRANSPLANTATION; REAL-TIME POLYMERASE CHAIN REACTION; T-LYMPHOCYTES; TUMOR MICROENVIRONMENT;

EID: 84954155380     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1501648     Document Type: Article

References (37)

1. Reungwetwattana, T., and G. K. Dy. 2013. Targeted therapies in development for non-small cell lung cancer. J. Carcinog. 12: 22.
2. Joyce, J. A., and J. W. Pollard. 2009. Microenvironmental regulation of metastasis. Nat. Rev. Cancer 9: 239-252.
3. Kenny, P. A., G. Y. Lee, and M. J. Bissell. 2007. Targeting the tumor micro-environment. Front. Biosci. 12: 3468-3474.
4. Cho, W. C., C. K. Kwan, S. Yau, P. P. So, P. C. Poon, and J. S. Au. 2011. The role of inflammation in the pathogenesis of lung cancer. Expert Opin. Ther. Targets 15: 1127-1137.
5. Peters-Golden, M., and W. R. Henderson, Jr. 2007. Leukotrienes. N. Engl. J. Med. 357: 1841-1854.
6. Pidgeon, G. P., J. Lysaght, S. Krishnamoorthy, J. V. Reynolds, K. O'Byrne, D. Nie, and K. V. Honn. 2007. Lipoxygenase metabolism: roles in tumor progression and survival. Cancer Metastasis Rev. 26: 503-524.
7. Steinhilber, D., A. S. Fischer, J. Metzner, S. D. Steinbrink, J. Roos, M. Ruthardt, and T. J. Maier. 2010. 5-lipoxygenase: underappreciated role of a pro-inflammatory enzyme in tumorigenesis. Front. Pharmacol. 1: 143.
8. Schwab, J. M., and C. N. Serhan. 2006. Lipoxins and new lipid mediators in the resolution of inflammation. Curr. Opin. Pharmacol. 6: 414-420.
9. Saif, M. W., H. Oettle, W. L. Vervenne, J. P. Thomas, G. Spitzer, C. Visseren-Grul, N. Enas, and D. A. Richards. 2009. Randomized double-blind phase II trial comparing gemcitabine plus LY293111 versus gemcitabine plus placebo in advanced adenocarcinoma of the pancreas. Cancer J. 15: 339-343.
10. Edelman, M. J., D. Watson, X. Wang, C. Morrison, R. A. Kratzke, S. Jewell, L. Hodgson, A. M. Mauer, A. Gajra, G. A. Masters, et al. 2008. Eicosanoid modulation in advanced lung cancer: cyclooxygenase-2 expression is a positive predictive factor for celecoxib + chemotherapy-Cancer and Leukemia Group B Trial 30203. J. Clin. Oncol. 26: 848-855.
11. Jänne, P. A., L. Paz-Ares, Y. Oh, C. Eschbach, V. Hirsh, N. Enas, L. Brail, and J. von Pawel. 2014. Randomized, double-blind, phase II trial comparing gemcitabine-cisplatin plus the LTB4 antagonist LY293111 versus gemcitabine-cisplatin plus placebo in first-line non-small-cell lung cancer. J. Thorac. Oncol. 9: 126-131.
12. Chen, Y., Y. Hu, H. Zhang, C. Peng, and S. Li. 2009. Loss of the Alox5 gene impairs leukemia stem cells and prevents chronic myeloid leukemia. Nat. Genet. 41: 783-792.
13. Cheon, E. C., K. Khazaie, M. W. Khan, M. J. Strouch, S. B. Krantz, J. Phillips, N. R. Blatner, L. M. Hix, M. Zhang, K. L. Dennis, et al. 2011. Mast cell 5-lipoxygenase activity promotes intestinal polyposis in APCDelta468 mice. Cancer Res. 71: 1627-1636.
14. Cheon, E. C., M. J. Strouch, S. B. Krantz, M. J. Heiferman, and D. J. Bentrem. 2012. Genetic deletion of 5-lipoxygenase increases tumor-infiltrating macro-phages in Apc(Delta468) mice. J. Gastrointest. Surg. 16: 389-393.
15. Li, H., A. L. Sorenson, J. Poczobutt, J. Amin, T. Joyal, T. Sullivan, J. T. Crossno, Jr., M. C. Weiser-Evans, and R. A. Nemenoff. 2011. Activation of PPARg in myeloid cells promotes lung cancer progression and metastasis. PLoS One 6: e28133.
16. Poczobutt, J. M., M. Gijon, J. Amin, D. Hanson, H. Li, D. Walker, M. Weiser-Evans, X. Lu, R. C. Murphy, and R. A. Nemenoff. 2013. Eicosanoid profiling in an orthotopic model of lung cancer progression by mass spectrometry demonstrates selective production of leukotrienes by inflammatory cells of the mi-croenvironment. PLoS One 8: e79633.
17. Weiser-Evans, M. C., X. Q. Wang, J. Amin, V. Van Putten, R. Choudhary, R. A. Winn, R. Scheinman, P. Simpson, M. W. Geraci, and R. A. Nemenoff. 2009. Depletion of cytosolic phospholipase A2 in bone marrow-derived mac-rophages protects against lung cancer progression and metastasis. Cancer Res. 69: 1733-1738.
18. Weidner, N. 1995. Current pathologic methods for measuring intratumoral microvessel density within breast carcinoma and other solid tumors. Breast Cancer Res. Treat. 36: 169-180.
19. Lone, A. M., and K. Taskén. 2013. Proinflammatory and immunoregulatory roles of eicosanoids in T cells. Front. Immunol. 4: 130.
20. Duan, M., W. C. Li, R. Vlahos, M. J. Maxwell, G. P. Anderson, and M. L. Hibbs. 2012. Distinct macrophage subpopulations characterize acute infection and chronic inflammatory lung disease. J. Immunol. 189: 946-955.
21. Gautier, E. L., T. Shay, J. Miller, M. Greter, C. Jakubzick, S. Ivanov, J. Helft, A. Chow, K. G. Elpek, S. Gordonov, et al; Immunological Genome Consortium. 2012. Gene-expression profiles and transcriptional regulatory pathways that underlie the identity and diversity of mouse tissue macrophages. Nat. Immunol. 13: 1118-1128.
22. Janssen, W. J., L. Barthel, A. Muldrow, R. E. Oberley-Deegan, M. T. Kearns, C. Jakubzick, and P. M. Henson. 2011. Fas determines differential fates of resident and recruited macrophages during resolution of acute lung injury. Am. J. Respir. Crit. Care Med. 184: 547-560.
23. Sapieha, P., A. Stahl, J. Chen, M. R. Seaward, K. L. Willett, N. M. Krah, R. J. Dennison, K. M. Connor, C. M. Aderman, E. Liclican, et al. 2011. 5-Lipoxygenase metabolite 4-HDHA is a mediator of the antiangiogenic effect of v-3 polyunsaturated fatty acids. Sci. Transl. Med. 3: 69ra12.
24. Wang, D., and R. N. Dubois. 2010. Eicosanoids and cancer. Nat. Rev. Cancer 10: 181-193.
25. Buczynski, M. W., D. S. Dumlao, and E. A. Dennis. 2009. Thematic Review Series: Proteomics. An integrated omics analysis of eicosanoid biology. J. Lipid Res. 50: 1015-1038.
26. Keith, R. L., Y. E. Miller, Y. Hoshikawa, M. D. Moore, T. L. Gesell, B. Gao, A. M. Malkinson, H. A. Golpon, R. A. Nemenoff, and M. W. Geraci. 2002. Manipulation of pulmonary prostacyclin synthase expression prevents murine lung cancer. Cancer Res. 62: 734-740.
27. Yuan, H., M. Y. Li, L. T. Ma, M. K. Hsin, T. S. Mok, M. J. Underwood, and G. G. Chen. 2010. 15-Lipoxygenases and its metabolites 15(S)-HETE and 13(S)-HODE in the development of non-small cell lung cancer. Thorax 65: 321-326.
28. Ghosh, J., and C. E. Myers. 1998. Inhibition of arachidonate 5-lipoxygenase triggers massive apoptosis in human prostate cancer cells. Proc. Natl. Acad. Sci. USA 95: 13182-13187.
29. Ding, X. Z., P. Iversen, M. W. Cluck, J. A. Knezetic, and T. E. Adrian. 1999. Lipoxygenase inhibitors abolish proliferation of human pancreatic cancer cells. Biochem. Biophys. Res. Commun. 261: 218-223.
30. Ding, X. Z., W. G. Tong, and T. E. Adrian. 2003. Multiple signal pathways are involved in the mitogenic effect of 5(S)-HETE in human pancreatic cancer. Oncology 65: 285-294.
31. Tong, W. G., X. Z. Ding, M. S. Talamonti, R. H. Bell, and T. E. Adrian. 2005. LTB4 stimulates growth of human pancreatic cancer cells via MAPK and PI-3 kinase pathways. Biochem. Biophys. Res. Commun. 335: 949-956.
32. Goodarzi, K., M. Goodarzi, A. M. Tager, A. D. Luster, and U. H. von Andrian. 2003. Leukotriene B4 and BLT1 control cytotoxic effector T cell recruitment to inflamed tissues. Nat. Immunol. 4: 965-973.
33. Sharma, R. K., Z. Chheda, V. R. Jala, and B. Haribabu. 2013. Expression of leukotriene B4 receptor-1 on CD8? T cells is required for their migration into tumors to elicit effective antitumor immunity. J. Immunol. 191: 3462-3470.
34. Tager, A. M., S. K. Bromley, B. D. Medoff, S. A. Islam, S. D. Bercury, E. B. Friedrich, A. D. Carafone, R. E. Gerszten, and A. D. Luster. 2003. Leu-kotriene B4 receptor BLT1 mediates early effector T cell recruitment. Nat. Immunol. 4: 982-990.
35. Ganesh, R., D. J. Marks, K. Sales, M. C. Winslet, and A. M. Seifalian. 2012. Cyclooxygenase/lipoxygenase shunting lowers the anti-cancer effect of cyclooxygenase-2 inhibition in colorectal cancer cells. World J. Surg. Oncol. 10: 200.
36. Serhan, C. N. 2014. Pro-resolving lipid mediators are leads for resolution physiology. Nature 510: 92-101.
37. DiMeo, D., J. Tian, J. Zhang, S. Narushima, and D. J. Berg. 2008. Increased interleukin-10 production and Th2 skewing in the absence of 5-lipoxygenase. Immunology 123: 250-262.